Cyclacel Pharmaceuticals Reports Q3 2024 Results
Ticker: BGMSP · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 1130166
| Field | Detail |
|---|---|
| Company | Cyclacel Pharmaceuticals, INC. (BGMSP) |
| Form Type | 10-Q |
| Filed Date | Nov 12, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001, $000, $2.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, warrants
Related Tickers: CYCC
TL;DR
Cyclacel Pharma (CYCC) Q3 2024 10-Q shows net loss, details on warrants. Cash position key.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the period. Key financial data includes cash and cash equivalents, and details on warrants and their valuation inputs like risk-free interest rates and expected terms as of September 30, 2024.
Why It Matters
This filing provides insight into Cyclacel's financial health and operational status for the third quarter of 2024, which is crucial for investors assessing the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company with a net loss, Cyclacel faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 335273 — Total Assets (Reported for the period ending 2024-09-30)
- 1058892 — Total Liabilities (Reported for the period ending 2024-09-30)
- 2152202 — Total Equity (Reported for the period ending 2024-09-30)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of reporting period
- 20241112 (date) — Filing date
- 0001130166 (company) — Central Index Key for Cyclacel Pharmaceuticals, Inc.
FAQ
What was Cyclacel Pharmaceuticals' net loss for the period ending September 30, 2024?
The filing indicates a net loss for the period, though the exact dollar amount is not explicitly stated in the provided snippet.
What are the key valuation inputs for Cyclacel's common stock warrants as of September 30, 2024?
Key valuation inputs include risk-free interest rate, price volatility, and expected term, with both minimum and maximum values provided for these metrics.
When was Cyclacel Pharmaceuticals, Inc. formerly known as XCYTE THERAPIES INC?
The company's name change from XCYTE THERAPIES INC occurred on December 18, 2000.
What is the SIC code for Cyclacel Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Cyclacel Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of Cyclacel Pharmaceuticals, Inc.?
The business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Stats: 4,634 words · 19 min read · ~15 pages · Grade level 17.9 · Accepted 2024-11-12 17:10:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Stock Mar
- $000 — INC. CONSOLIDATED BALANCE SHEETS (In $000s, except share, per share, and liquidat
- $2.5 million — orted stockholders' equity of less than $2.5 million as of June 30, 2024. The notice from th
Filing Documents
- cycc-20240930x10q.htm (10-Q) — 1483KB
- cycc-20240930xex31d1.htm (EX-31.1) — 14KB
- cycc-20240930xex31d2.htm (EX-31.2) — 15KB
- cycc-20240930xex32d1.htm (EX-32.1) — 5KB
- cycc-20240930xex32d2.htm (EX-32.2) — 5KB
- cycc-20240930x10q001.jpg (GRAPHIC) — 19KB
- cycc-20240930x10q002.jpg (GRAPHIC) — 33KB
- 0001558370-24-015349.txt ( ) — 6157KB
- cycc-20240930.xsd (EX-101.SCH) — 46KB
- cycc-20240930_cal.xml (EX-101.CAL) — 35KB
- cycc-20240930_def.xml (EX-101.DEF) — 225KB
- cycc-20240930_lab.xml (EX-101.LAB) — 360KB
- cycc-20240930_pre.xml (EX-101.PRE) — 310KB
- cycc-20240930x10q_htm.xml (XML) — 842KB
Financial Information
Part I. Financial Information Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 3 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31
Other Information
Part II. Other Information Item 1.
Legal Proceedings
Legal Proceedings 32 Item 1A.
Risk Factors
Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 33 SIGNATURE PAGE 34 2 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements CYCLACEL PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS (In $000s, except share, per share, and liquidation preference amounts) (Unaudited) September 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 2,982 $ 3,378 Prepaid expenses and other current assets 1,931 4,066 Total current assets 4,913 7,444 Property and equipment, net 4 9 Right-of-use lease asset 51 93 Non-current deposits 413 1,259 Total assets $ 5,381 $ 8,805 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 4,126 $ 3,543 Accrued and other current liabilities 2,225 4,618 Total current liabilities 6,351 8,161 Lease liability — 37 Total liabilities 6,351 8,198 Stockholders' equity (deficit): Preferred stock, $ 0.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; 6 % Convertible Exchangeable preferred stock; 335,273 shares issued and outstanding at September 30, 2024 and December 31, 2023. Aggregate preference in liquidation of $ 4,157,385 as of September 30, 2024 and December 31, 2023 — — Series A convertible preferred stock, $ 0.001 par value; 264 shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Series B convertible preferred stock, $ 0.001 par value; 0 shares issued and outstanding at September 30, 2024 and 119,000 shares issued and outstanding at December 31, 2023 — — Common stock, $ 0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 2,152,202 shares issued and outstanding at September 30, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023 2 1 Additional paid-in capital 436,503 429,796 Accumulated other comprehensive loss ( 1,033 ) ( 908 ) Accumulated deficit ( 436,442 ) ( 428,282 ) Total stockholders' equity (deficit) ( 970 ) 607 Total liabilities and stockhold